| Literature DB >> 28971769 |
Mateus Feitosa Alves1, Diogo Vilar da Fonseca2, Silvia Adelaide Linhares de Melo3, Marcus Tullius Scotti1, Luciana Scotti1, Socrates Golzio Dos Santos4, Margareth de Fatima Formiga Melo Diniz1.
Abstract
Asthma is an inflammatory disease which affects millions of people worldwide. Therefore, it is necessary to search for new sources of therapies for the treatment of these patients in order to improve their quality of life. From content analysis of literature of new therapeutic targets, there are various targets and drugs reported to be promising for the treatment of asthma. Interleukins involved in inflammatory processes are often presented as candidate targets for new drugs. The action of such therapeutics would not only affect interleukins, but also their receptors. Small molecules (e.g. ligustrazine and SP600125) and large molecule antibodies (e.g. lebrikizumab, benralizumab, dupilumab) are being considered as novel agents for the pharmacotherapy of asthma. Therefore, through this research, we can see advances in the search for new targets and promising drugs to treat asthma. It is expected that these new drug candidates will eventually be approved and marketed so that asthma patients can use them to enhance their quality of life. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.Entities:
Keywords: Asthma; drugs; monoclonal antibody; natural products; targets; therapeutic targets.
Mesh:
Substances:
Year: 2018 PMID: 28971769 DOI: 10.2174/1389557517666170927145011
Source DB: PubMed Journal: Mini Rev Med Chem ISSN: 1389-5575 Impact factor: 3.862